Genetic causes of deadly focal segmental glomerulosclerosis

Genetic causes of deadly focal segmental glomerulosclerosis

Focal Segmental Glomerulosclerosis (FSGS)?

Focal Segmental Glomerulosclerosis (FSGS) is an uncommon but deadly kidney disease that causes protein loss in urine, edema, and kidney failure by scarring the glomeruli. FSGS can be primary (no known cause), secondary (due to diabetes, HIV, lupus, or obesity), or genetic. Treatment aims to delay progression, manage symptoms, and prevent kidney failure.

Focal Segmental Glomerulosclerosis

Symptoms

• Edema: Leg, ankle, or ocular swelling.
• Proteinuria causes foamy urine.
• Fluid retention causes weight gain.
• Blood pressure and cholesterol are high.
• Fatigue, appetite loss, and nausea in advanced stages.

Types and Causes

• Primary FSGS: Unknown cause.
• Secondary FSGS: Because of diabetes, lupus, HIV, obesity, sickle cell disease, or medication toxicity.
• Genetic FSGS: Familial APOL1 gene mutations.
• The cause of FSGS is unknown despite testing.

Living With FSGS

• Regular blood/urine tests.
• Stop smoking, exercise, and maintain a healthy weight.
• Early swelling or frothy urine detection is crucial.
• Some individuals enter remission and maintain renal function for years.

FSGS types

Primary FSGS

• Idiopathic FSGS.
• Has no known cause.
• This condition may be caused by cytokines or antibodies that destroy podocytes.
• Nephrotic syndrome (proteinuria, edema, low albumin) often occurs unexpectedly.

Secondary FSGS

• Causes of secondary FSGS include HIV, hepatitis B/C, COVID-19, diabetes, lupus, obesity, sickle cell disease, anabolic steroids, heroin, interferon, and lithium.
• Proteinuria and hypertension cause progressive development.

Genetic FSGS

Also familial FSGS.

• It is caused by podocyte or glomerular membrane gene alterations (NPHS2, COL4A3, COL4A4, APOL1).
• It often occurs in childhood, presenting as severe nephrotic syndrome and inadequate immunosuppression.
• The affected family should have genetic testing.

Unknown FSGS

• When testing fails to identify a cause.
• Managed with supportive therapy and regular monitoring.

Disease Variants (Biopsy Subtypes)

• Histological variants under the microscope describe FSGS beyond clinical classification:
• Tip lesion—tubular pole lesion; steroid-responsive improved prognosis.
• Perihilar variant—common in adults and obesity-related secondary FSGS; associated to high filtration pressures.
• Hypercellular variation may indicate early illness.
• Collapsing variant—aggressive, commonly linked to HIV or APOL1 mutations; fast renal failure.

How to Diagnose FSGS?

Main Diagnostic Steps

• Health history and exam
• Doctors assess for edema, high blood pressure, diabetes, lupus, obesity, and a family history of renal disease.

Urine testing

• Check for proteinuria and hematuria.
• Clinical clues include foamy urine.

Tests of blood

• Test creatinine, BUN, albumin, cholesterol, and electrolytes.
• Rate of glomerular filtration
• Estimates kidney blood filtering.
• Kidney injury is indicated by declining GFR.

Imaging tests

• CT or ultrasound can rule out structural problems.
• A kidney biopsy

The diagnostic gold standard.

• A microscope detects focal and segmental scarring in a tiny tissue sample.
• Helps differentiate tip, perihilar, cellular, and collapsing FSGS variations.

Genetic testing

• Recommended for resistant or family cases.
• Mutations like NPHS2 and APOL1 affect prognosis and treatment.

Why Biopsy Matters

• FSGS mimics minimal change disease and other renal disorders.
• Only a biopsy can confirm segmental scarring.
• Helps personalize treatment: steroids may assist primary FSGS but not hereditary variants.

Options for FSGS treatment

• Main Treatment Methods
• Corticosteroids
• Initial FSGS treatment.
• Reduce immune activity and proteinuria.
• High doses have negative effects; thus, newer regimens use lower amounts or combine medications.

CNIs suppress calcineurin

• Used when steroids fail or create negative effects.
• Tacrolimus, Cyclosporine.
• Compatible with low-dose steroids.

Alternative immunosuppressants

• Mycophenolate mofetil, rituximab, obinutuzumab, cyclophosphamide, and ACTH are options.
• These options are for resistant or intolerant situations.

New hope for FSGS: watch this video.

Supportive Therapies

• ARBs/ACE inhibitors
• Reduce blood pressure and urine protein loss.
• Usually prescribed long-term.
• Diuretics
• Edema can be managed by eliminating excess fluid.

Statins

• Manage nephrotic syndrome-related elevated cholesterol.

Changes in diet: 

• Low salt and protein.
• Kidney failure requires dialysis or a transplant.

Risks, complications

• Nephrotic syndrome: Protein loss, clotting, hypertension.
• Dialysis/transplant for irreversible kidney failure.
• Many people develop end-stage renal disease within 6–8 years without treatment.

Developing Treatments

• Sparsentan was FDA-approved in April 2026. It blocks endothelin A and angiotensin II type 1. It is not for ACE inhibitors or ARBs.
• Inaxaplin: APOL1 gene variations linked to treatment resistance are being studied.
• Obinutuzumab: Antibody treatment appears promising for resistant instances.

Risks and Factors

• The FSGS type (primary, secondary, hereditary, or undetermined) determines treatment.
• Steroids can affect secondary FSGS patients; thus, finding the aetiology is crucial.
• Genetic testing, especially for African APOL1 variations, guides treatment.
• Detecting remission, recurrence, and renal failure requires long-term monitoring.

FSGS genetic hazards

• Key genetic risk factors
• NPHS2 gene
• It encodes podocin, a vital glomerular filtration protein.
• Steroid-resistant FSGS is common in youngsters due to mutations.

COL4A3/COL4A4 genes

• Type IV collagen is needed for the glomerular basement membrane.
• Variants can cause kidney disease, including Alport syndrome.

JAG1 gene

• Related to Notch signalling.
• Abnormal kidney development and FSGS risk mutations.

Gene variations: APOL1

• Common among Africans.
• These variations are linked to aggressive, treatment-resistant FSGS and quicker renal failure.

Kids' Genetic Risks

• Novel genetic risk factors beyond NPHS2 include podocyte shape and immunological signaling gene variations in children.
• Genetic testing in pediatric FSGS distinguishes inherited from acquired types and guides treatment.

Risks Factors

• Steroid resistance: Genetic FSGS rarely responds to typical immunosuppression.
• Risk: APOL1 variants accelerate kidney failure.
• Family screening: Genetic testing for relatives is advised.
• Treatment tailoring: Mutations help prevent unsuccessful medications and suggest supportive care or innovative drugs (e.g., inaxaplin for APOL1-related FSGS).

FSGS complications

• Nephrotic disease
• Extreme proteinuria, low albumin, swelling, and high cholesterol.
• Increases infection and blood clot risk.

Long-term kidney disease

• Deterioration of renal function.
• Becoming end-stage renal disease.

End-stage renal disease

• Kidneys fail, needing dialysis or a transplant.
• Untreated patients often develop ESRD in 6–8 years.

Hypertension

• High blood pressure damages the kidneys.
• Common in secondary FSGS.

Cardiovascular disease

• Hypertension and high cholesterol raise stroke and heart attack risk.

Blood clots

• Protein loss affects coagulation.
• DVT/PE risk.

Infections

• Urine immunoglobulin loss reduces immunity.
• Patients with this condition are more prone to respiratory and skin diseases.

Conclusion

In conclusion, Focal Segmental Glomerulosclerosis (FSGS) is a complicated kidney disease that causes protein loss, edema, and kidney damage due to glomerular scarring.

Slowing disease development and minimizing consequences requires early detection, correct categorization, and targeted treatment. Patients now have more focused treatment options than ever, thanks to sparsentan and genetic research. To preserve kidney function and quality of life with FSGS, patients need monitoring, lifestyle changes, and close collaboration with healthcare specialists.